279 related articles for article (PubMed ID: 18329793)
41. Review: on TRAIL for malignant glioma therapy?
Kuijlen JM; Bremer E; Mooij JJ; den Dunnen WF; Helfrich W
Neuropathol Appl Neurobiol; 2010 Apr; 36(3):168-82. PubMed ID: 20102513
[TBL] [Abstract][Full Text] [Related]
42. Dexamethasone counteracts the anti-osteoclastic, but not the anti-leukemic, activity of TNF-related apoptosis inducing ligand (TRAIL).
Zauli G; Rimondi E; Celeghini C; Milani D; Secchiero P
J Cell Physiol; 2010 Feb; 222(2):357-64. PubMed ID: 19877156
[TBL] [Abstract][Full Text] [Related]
43. Ribosomal protein S6 is a selective mediator of TRAIL-apoptotic signaling.
Jeon YJ; Kim IK; Hong SH; Nan H; Kim HJ; Lee HJ; Masuda ES; Meyuhas O; Oh BH; Jung YK
Oncogene; 2008 Jul; 27(31):4344-52. PubMed ID: 18362888
[TBL] [Abstract][Full Text] [Related]
44. Targeting XIAP bypasses Bcl-2-mediated resistance to TRAIL and cooperates with TRAIL to suppress pancreatic cancer growth in vitro and in vivo.
Vogler M; Walczak H; Stadel D; Haas TL; Genze F; Jovanovic M; Gschwend JE; Simmet T; Debatin KM; Fulda S
Cancer Res; 2008 Oct; 68(19):7956-65. PubMed ID: 18829553
[TBL] [Abstract][Full Text] [Related]
45. Upregulation of DR5 by proteasome inhibitors potently sensitizes glioma cells to TRAIL-induced apoptosis.
Hetschko H; Voss V; Seifert V; Prehn JH; Kögel D
FEBS J; 2008 Apr; 275(8):1925-36. PubMed ID: 18341587
[TBL] [Abstract][Full Text] [Related]
46. Enhancement of antitumor properties of rhTRAIL by affinity increase toward its death receptors.
Reis CR; van der Sloot AM; Szegezdi E; Natoni A; Tur V; Cool RH; Samali A; Serrano L; Quax WJ
Biochemistry; 2009 Mar; 48(10):2180-91. PubMed ID: 19236007
[TBL] [Abstract][Full Text] [Related]
47. Anti-gout agent allopurinol exerts cytotoxicity to human hormone-refractory prostate cancer cells in combination with tumor necrosis factor-related apoptosis-inducing ligand.
Yasuda T; Yoshida T; Goda AE; Horinaka M; Yano K; Shiraishi T; Wakada M; Mizutani Y; Miki T; Sakai T
Mol Cancer Res; 2008 Dec; 6(12):1852-60. PubMed ID: 19074830
[TBL] [Abstract][Full Text] [Related]
48. Susceptibility of the C2 canine mastocytoma cell line to the effects of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL).
Elders RC; Baines SJ; Catchpole B
Vet Immunol Immunopathol; 2009 Jul; 130(1-2):11-6. PubMed ID: 19185923
[TBL] [Abstract][Full Text] [Related]
49. Kaempferol sensitizes colon cancer cells to TRAIL-induced apoptosis.
Yoshida T; Konishi M; Horinaka M; Yasuda T; Goda AE; Taniguchi H; Yano K; Wakada M; Sakai T
Biochem Biophys Res Commun; 2008 Oct; 375(1):129-33. PubMed ID: 18680719
[TBL] [Abstract][Full Text] [Related]
50. High levels of endogenous tumor necrosis factor-related apoptosis-inducing ligand expression correlate with increased cell death in human pancreas.
Sanlioglu AD; Dirice E; Elpek O; Korcum AF; Balci MK; Omer A; Griffith TS; Sanlioglu S
Pancreas; 2008 May; 36(4):385-93. PubMed ID: 18437085
[TBL] [Abstract][Full Text] [Related]
51. Histone deacetylase inhibitors cooperate with IFN-gamma to restore caspase-8 expression and overcome TRAIL resistance in cancers with silencing of caspase-8.
Häcker S; Dittrich A; Mohr A; Schweitzer T; Rutkowski S; Krauss J; Debatin KM; Fulda S
Oncogene; 2009 Sep; 28(35):3097-110. PubMed ID: 19597472
[TBL] [Abstract][Full Text] [Related]
52. The pleiotropic effect of TRAIL on tumor-like synovial fibroblasts from rheumatoid arthritis patients is mediated by caspases.
Audo R; Combe B; Coulet B; Morel J; Hahne M
Cell Death Differ; 2009 Sep; 16(9):1227-37. PubMed ID: 19407827
[TBL] [Abstract][Full Text] [Related]
53. Daidzein overcomes TRAIL-resistance in malignant glioma cells by modulating the expression of the intrinsic apoptotic inhibitor, bcl-2.
Siegelin MD; Gaiser T; Habel A; Siegelin Y
Neurosci Lett; 2009 May; 454(3):223-8. PubMed ID: 19429088
[TBL] [Abstract][Full Text] [Related]
54. Tumour necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced chemokine release in both TRAIL-resistant and TRAIL-sensitive cells via nuclear factor kappa B.
Tang W; Wang W; Zhang Y; Liu S; Liu Y; Zheng D
FEBS J; 2009 Jan; 276(2):581-93. PubMed ID: 19120450
[TBL] [Abstract][Full Text] [Related]
55. Cytotoxic effects of camptothecin and cisplatin combined with tumor necrosis factor-related apoptosis-inducing ligand (Apo2L/TRAIL) in a model of primary culture of non-small cell lung cancer.
Frese S; Schüller A; Frese-Schaper M; Gugger M; Schmid RA
Anticancer Res; 2009 Aug; 29(8):2905-11. PubMed ID: 19661294
[TBL] [Abstract][Full Text] [Related]
56. Spatial dynamics of TRAIL death receptors in cancer cells.
Twomey JD; Kim SR; Zhao L; Bozza WP; Zhang B
Drug Resist Updat; 2015 Mar; 19():13-21. PubMed ID: 25840763
[TBL] [Abstract][Full Text] [Related]
57. Clearing the TRAIL for Cancer Therapy.
Hall MA; Cleveland JL
Cancer Cell; 2007 Jul; 12(1):4-6. PubMed ID: 17613431
[TBL] [Abstract][Full Text] [Related]
58. TRAIL-receptor antibodies as a potential cancer treatment.
Buchsbaum DJ; Forero-Torres A; LoBuglio AF
Future Oncol; 2007 Aug; 3(4):405-9. PubMed ID: 17661715
[TBL] [Abstract][Full Text] [Related]
59. The TRAIL to cancer therapy: Hindrances and potential solutions.
Wong SHM; Kong WY; Fang CM; Loh HS; Chuah LH; Abdullah S; Ngai SC
Crit Rev Oncol Hematol; 2019 Nov; 143():81-94. PubMed ID: 31561055
[TBL] [Abstract][Full Text] [Related]
60. Targeting TRAIL towards the clinic.
Mahalingam D; Oldenhuis CN; Szegezdi E; Giles FJ; de Vries EG; de Jong S; Nawrocki ST
Curr Drug Targets; 2011 Dec; 12(14):2079-90. PubMed ID: 21777191
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
